Gastrointestinal Stromal Tumors are uncommon mesenchimal tumors that arise in the wall of the gastrointestinal tract.
They account for approximately 0,1% to 3% of all gastrointestinal neoplasms, with about 150 new cases per year diagnosed in the United States.
The term GIST first used by Mazur and Clark in 1983 includes a heterogeneous group of nonepithelial neoplasms with spindle or epithelioid cells, which display a range of differentiation (Crosby).
It is difficult to determine microscopically the exact origin of these tumors.
They have a complicated histogenesis and moreover it is not easy to assign a benign or malignant classification; for these reasons the non-specific term Gastrointestinal Stromal Tumor, GIST has been coined (Pidhorecky ).
Immunohistochemistry and electron microscopy introduced the new evidence that GISTs may have myogenic features (smooth muscle GISTs), neural attributes (gastrointestinal anatomic nerve tumor), or characteristic of both muscle and nerve (mixed GISTs), or may lack differentiation (GISTs not otherwise specified).
The Cajal cell, an intestinal pacemaker cell, has been proposed the cellular origin of GISTs, having both cell markers in common. It has characteristics of both smooth muscle and neural differentiation on ultrastructural esamination ( DeMatteo).
The authors don't take care of specifing the histologic subtypes because at the present it is not clear whether a clinical difference exists between the subtypes of GISTs.
Furthermore no histologic grading system has been established for this group of tumors
( Mudan ).
Grossly GISTs are smooth gray - white tumors which arise within the muscolaris propria of the GI tract. They are well circumscribed and containe a pseudocapsule. They may grow in an endophytic fashion compromising bowel lumen patency or may exhibit an exophytic or dumbbell growth pattern. In GISTs with an endophytic component
the submucosal mass may have an overlying mucosal necrosis and ulceration.
At a intraoperative appearance it is possible to distinguish a mass attached to the stomach or the bowel wall projecting into the abdominal cavity, displacing other organs.
Malignant GISTs are characterized by the invasion of adjacent structures and by the presence of multiple nodules in the surrounding tissue , or evident metastatic disease (Pidhorecky).
The mean age of patients is 58.5 years (range 22-79 years). (Yao).
The risk factors and etiology of GISTs remain undetermined (Pidhorecky).
Because of the nonspecific symptoms, a delayed diagnosis is generally associated with Gastrointestinal Stromal Tumors, with a mean duration of symptoms before presentation of 6 months.
The most frequent clinical manifestations are gastrointestinal bleeding, a palpable mass and mild abdominal pain in order of frequency.
Over 5% of patients has more than 1 complaint or physical findings.
There isn't a correlation of these symptoms with prognosis
The most frequent diagnostic test is CT; it can demonstrate a mass lesion , the contigous organ invasion and distant metastases.
CT (in particular spiral CT scan with thin cuts ) is the most sensitive test for the detection and staging of a primary gastrointestinal sarcoma, in respect to other imaging tests (upper gastrointestinal contrast study, abdominal ultrasound scanning, angiography).
Endoscopic ultrasound would be helpful to assess pancreatic involvement, whether mucosal ulceration is due to sarcoma or due to a non stromal tumor, and to assess involvement in the lower gastrointestinal tract.
Patients with upper gastrointestinal bleeding are submitted to upper endoscopy
The most common anatomic locations are the stomach (53%), the small intestine (33%), rectum (5%), esophagus (5%) and colon (4%).
The location of the tumor is not considered a significant prognostic factor
Preoperative percutaneous biopsy carries the theoretical risk of peritoneal seeding or tumor rupture. It is indicated only for clearly unresectable disease or when treatment would be altered , as would be the case if the mass proved to be a lymphoma or germ cell tumor.
Only highly experienced pathologists are likely to provide a diagnosis with a intraoperative frozen section. (DeMatteo ).
Until more effective adjuvant therapy becomes available , the treatment of GISTs remains primarly surgical.
Every effort should be made to achieve complete resection of all gross disease , sometimes necessitating the removal of adjacent organs.
Incomplete resection should be performed only for the palliation of symptoms due to bleeding , pain, or mass effect. It is defined complete resection the excision of all gross disease , regardless of microscopic margins. ( DeMatteo ).
It is essential to avoid tumor spillage or tumor rupture in the abdomen. They have been associated with an increased risk of peritoneal recurrence (Pidhorecky).
Systematic limph node dissection is not thought to be necessary for surgical management of gastric leiomyosarcoma . Although laparoscopic wedge resection is not indicated for tumors at inappropriate locations, such as the cardia or pylorus or large tumors resulting in postoperative stenosis, this procedure is appropriate for tumors located in others parts of the posterior and anterior wall of the stomach
( Yoshida ).
For small bowel stromal tumors Crosby reccomends an attempt at preoperative diagnosis, careful surgical planning and an effort to achieve complete gross resection in patients with malignant small intestinal GISTs even in the presence of local invasion.
He finds no correlation between tumor grade and clinical behaviour in the 50 patients study. Even patients with histologically benign lesions and no detectable mitotic figures can develop metastases and die of disease ( Crosby).
Yao , with some difference, does not advocate extended lymphadenectomy for gastric lesions. He advocates to remove the perigastric nodes and omentum. For small bowel lesions it is recommendable to remove the adjacent mesentery; for colon and rectal lesions the mesocolon or the mesorectum
The overall survival rate for all patients has been 35% at 5 years.
Patients with complete resection had a 54% 5 year survival rate . Patients who could not undergo complete resection had a median survival of only 12 months; median survival was 19 months in those with metastases and 12 months in those with local recurrence.
In the entire population male sex, tumor size >5cm and incomplete resection have been significant predictors of survival on multivariate analysis.
In the patients without metastases and who underwent complete gross resection size has been an important predictor of survival on both univariate and multivariate analysis. Tumor size >10cm has been the most significant factor.
The status of the microscopic margin of resection does not affect survival . Many of this tumors are exophytic and protrude into the abdominal cavity , therefore the microscopic margin of resection may not be as important as whether the tumor sheds cells directly into the peritoneal cavity ( DeMatteo).
Recurrence of GIST is usual and one report find only 10% of patients to be free of disease after long term follow up.
Recurrence of the disease after resection is predominantly intraabdominal and involves the original tumor site, peritoneum and liver.
In the patients with primary disease who underwent complete resection the liver was involved in 63% of patients who had recurrence; this was the only site of the disease in 44% of recurrences.
Extrabdominal metastases are much less common ( 15%).
The status of microscopic margins of resection does not predict recurrence. (DeMatteo).
In multivariate analysis of postrecurrence survival, the length of the disease free interval between the initial operation and recurrence is the only significant determinant of survival .
The outcome for patients who achieve a CR of the recurrence is statistically the same for those who have incomplete resections.
Despite macroscopic and microscopic clearance , local recurrence seems to be predictive of the emergence of further local disease and progression to distant disease.
Those patients with isolated liver metastases show a trend toward better survival (PRSv of 34 months compared with 12 months for all others- postrecurrence survival , the time from diagnosis of the recurrence to tumor related death or the last follow up) however all of the patients who presented with the liver as the sole site of initial recurrence failed again by disease within the liver.
Except for patients with a long disease free interval second surgery should be restricted to symptom control.
The follow up of patients with curatively resected primary gastrointestinal sarcoma is a combination of clinical and appropriate imaging directed to the early identification of a small group of patients in whom failure is confined to the liver and in whom the potential for liver resection exists. (Mudan ).
There is currently no strong data to support the use of chemotherapy, other than in a controlled trial.
Intraperitoneal chemotherapy after cytoreductive surgery for abdominal sarcomatosis has been investigated by Karakousis et al. and Sugarbaker, with reported 5 year survival rates of 7% and 12% respectively.
A prospective study evaluating the role of intraperitoneal mitoxantrone after complete resection of abdominal sarcomas was recently published by Eilber et al.This approach had little effect on survival, as the rate of liver metastases was unaffected. However it did significantly affect the rate of peritoneal recurrence and thus may be of benefit to those patients with peritoneal-only disease.
Some authors have prompted the use of intraoperative radiotherapy in GISTs because it permits to deliver a meaningful amounts of radiation (Pidhorecky).
Photodynamic therapy (PDT) combining photosensitizer drug, oxygen and laser light has been designed to evaluate the effectiveness of surgical debulking and PDT in carcinomatosis and sarcomatosis (Hendren).
Yao KA et al. Primary gastrointestinal sarcomas : analysis of prognostic factors and results of surgical management. Surg 2000; 128: 604-612.
DeMatteo RP,et al. Two hundred gastrointestinal stromal tumors : recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
Mudan S, Conlon KC, Woodruff M, Lewis J, Brennan MF. Salvage surgery for patients with recurrent Gastrointestinal sarcoma. Cancer 2000; volume 88 : 66-74.
Pidhorecky I et al. Gastrointestinal stromal tumors: Current diagnosis, biologic behavior and management. Annals of Surgical Oncology, 2000; 7(9): 705-712.
Crosby JA et al. Malignant Gastrointestinal Stromal Tumors of the small intestine: a review of 50 cases from a prospective database. Annals of Surgical Oncology, 2001; 8(1): 50-59.
Gregory B. Davis et al. Tumors of the Stomach. World J Surg, 2000; 24, 412-420.
Lev D et al. Gastrointestinal stromal sarcomas. British Journal of Surgery 1999, 86, 545-549.
Carney JA. Gastric Stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carned triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clinic Proc 1999;74: 543-52.
Gibbs JF. Gastrointestinal Stromal tumors. Prob Gen. Surg 1999; 16: 107-13.
Chen H, et al. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg 1998;2:151-5.
Dodd LG et al. Fine needle aspiration of gastrointestinal Stromal tumors. Am J Clinic Pathol 1998; 109: 439-43.
Rocco G et al. Leiomyosarcoma of the esophagus: results of surgical treatment. Ann Thorac Surg 1998; 66: 894-7. .
Masashi Yoshida et al. Surgical management of gastric leiomyosarcoma : evaluation of propriety of laparoscopic wedge resection.World J Surg 21, 440-443, 1997.
Karakousis CP et al. Intraperitoneal chemotherapy in disseminated abdominal sarcoma. Ann Surg Oncol 1997 ; 4: 496-8.
Sugarbaker Ph. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998 ; 14:254-61.
Eilber FC et al. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999: 6:645-650.
Hendren SK et al. Phase II trial of debulking surgery and Photodinamic Therapy for disseminated intraperitoneal tumors. Annals of Surgical Oncology,2001; 8(1):65-67.
Kim NK et al. Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer. Dis Colon Rectum 1999;42:770-5.
Chak A et al. Endosonographic differentiatiation of benign and malignant stromal cell tumors. Gastrointestinal Endosc 1997; 45: 468-73.
Sell HW et al. Diffuse leiomyomatosis of the gastrointestinal tract in a single patient-esophagus to rectum: case report. Surgery1997; 122,3:637-40.
Ludwig DJ ,Traverso LW. Gut stromal tumors and their clinical behavior. Am J Surg 1997; 173:390-394.
LewisJJ, Brennan MF. Soft tissue sarcomas. Curr Prob Surg 1996; 33 (10): 817-72.
Suster S. Gastrointestinal stromal tumors. Sem Diag Pathol 1996; 13:297-313.
Chou F, et al. Smooth muscle tumors of the gastrointestinal tract : analysis of prognostic factors. Surgery 1996; 119:171-7.
Sanders L et al. Gastric smooth muscle tumors : diagnostic dilemmas and factors affecting outcome. World J Surg 1996; 20: 992-995.
Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995; 2:26-31.
Lewis JJ et al. Adjuvant therapy for soft tissue sarcomas. Sur Oncol Clinic North Am 1995;9 (4):801-15.
Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft tissue sarcoma. Ann Surg 1995; 221(4):392-97.
Horowitz J et al. An istitutional review of sarcomas of the large and small intestine. J Am Coll Surg 1995; 180:465-71.
Carson W et al. Results of aggressive treatment of gastric sarcoma. Ann Surg Oncol 1994;1(3):244-51.
Casper ES, Gaynor JJ, Harrison LB, Panicek D, Haidu SI, Brennan MF. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer 1994; 73:1644-51.
Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993; 217: 72-77.
Ng EH, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215:68-77.
Ng EH et al. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992; 69: 1334-1341.
Farrugia G et al. Leiomyosarcoma of the stomach : determinants of long term survival. Mayo Clin Proc. 67: 533,1992.
Kimura H, et al. Prognostic factors in primary gastrointestinal leiomyosarcomas : a retrospective study. World J Surg 1991; 15: 771-776.
Meijer S, Peretz T, Gaynor JJ, Tan C, Hajdu SI, Brennan MF. Primary colorectal sarcoma. Arch Surg 1990; 125: 1163-8.
Skandalakis JE, Gray SW . Smooth muscle tumors of the alimentary tract. In : Ariel IM, ed. Progress in Clinical Cancer. New York: Grune & Stratton; 1965: 692-708.
Miettinen M et al. Esophageal stromal tumors. Am J Surg Pathol 2000; 24(2):211-222.
Chan JK. Mesenchimal tumors of the gastrointestinal tract : a paradise for acronyms (STUMP, GIST,GANT, and now GI-PACT), implications of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal disease? Adv Anath Pathol 1999; 6:19-40.
Taniguchi M et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-300.
Siedal T et al. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumors. Histopathology 1999;34:416-24.
Sircar K et al. Interstitial cell of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-89.
Emory TS et al. Prognosis of smooth-muscle (Stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23:82-7.
Miettinen M et al. Gastrointestinal stromal tumors : recent advances in understanding of their biology. Hum Pathol 1999; 30: 1213-20.
Lasota J et al. Mutations in exon 11 of c-kit occurr preferentially in malignant versus benign gastrointestinal Stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154:53-60.
Sakurai S et al. Embryonic form of smooth muscle myosin heavy chain in gastrointestinal stromal tumor and interstitial cells of Cajal. Am J Pathol 1999; 154:23-8.
Sakuray S et al. Telomerase activity in gastrointestinal stromal tumors. Cancer 15, 1998; 83,10:2060-66.
Tworek JA et al. Stromal tumors of the abdominal colon. AM J Surg Pathol 23(8): 937-45, 1999.
Tworek JA et al. Stromal tumors of the anorectum. AM J Surg Pathol 23(8): 946-54, 1999.
Wu SS et al.Congenital gastrointestinal pacemaker cell tumor. Arch Pathol Lab Med 1999 123 :842-5.
Ernst SI et al. KIT mutation portends poor prognosis in gastrointestinal Stromal /smooth muscle tumors. Lab Invest 1998; 78: 1633-6.
Moskaluk CA et al.Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999; 18:1897-1902.
Tazawa K et al.An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol Int 1999; 49 :786-98.
Chang MS et al.Small intestinal stromal tumors : a clinicopathologic study of 31 tumors. Pathol Int 1998; 48: 341-7.
Ballarini C et al. Gastrointestinal stromal tumors: a "benign"tumor with hepatic metastases after 11 years. Tumori 1998; 84: 78-81.
Rudolph P et al.Immunophenothype, proliferation DNA. ploydy, and biological behavior of gastrointestinal Stromal tumors: a multivariate clinico-pathologic study. Hum Pathol 1998; 29: 791-800.
Kinblom LG, et al. Gastrointestinal pacemaker cell tumor: gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259-1269.
Hirota S, et al. Gain-of function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
Erlandson RA et al. Subclassification of gastrointestinasl stromal tumors based on evaluation by electron microscopy and immunohistochemistry. Ultrastruct Pathol 1996; 20:373-393.
Franquemont DW. Differentiation and risk assessment of gastrointestinal Stromal tumors. Am J Clinic Pathol 1995; 103:41-7.
Dougherty MJ et al. Sarcomas of the gastrointestinal tract. Separation into favourable and unfavourable prognostic groups by mitotic count. Ann Surg 1991; 214: 569-574.
Lauwers GY, Erlandson RA, Casper ES, Brennan MF, Woodruff JM. Gastrointestinal autonomic nerve tumors. A clinicopathological, immunohistochemical, and ultrastructural study of 12 cases. Am J Surg Pathol 1993; 17: 887-897.
Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983; 7:507-19.
Shiu MH et al. Myosarcomas of the stomach : natural history,prognostic factors and management. Cancer 49:177, 1982.